
Recursion Pharmaceuticals, Inc.: financial statements
Price
$2.80
November 17, 2026Market cap $1.7B
What Ploutos Investor adds for Recursion Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 24% since Nov 2, 2026, when the 10-Q these figures come from was filed ($3.83 then, $2.91 on Nov 16, 2026). The figures date from before that move.10-Q
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
+29.4% a year over 2 years
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $45M | $59M | $75M | +29.4% |
| Cost of revenue | $43M | $45M | $71M | +29.1% |
| Gross profit | $2.0M | $14M | $3.7M | +36.9% |
| Operating income | -$350M | -$479M | -$648M | |
| Net income | -$328M | -$464M | -$645M | |
| Earnings per share | -$1.58 | -$1.69 | -$1.44 | |
| Earnings per share, basic | -$1.58 | -$1.69 | -$1.44 | |
| Margins | ||||
| Gross margin | 4.5% | 23.1% | 5.0% | |
| Operating margin | -785.3% | -814.1% | -867.9% | |
| Net margin | -736.0% | -788.0% | -863.4% | |
Financial statements
RXRX's revenue, profits and cash flows from 2019 to 2022, 4 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
By segment
Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.
- License And Service
- Grant
- 2023: License And Service $44M, Grant $699.0K
- 2024: License And Service $58M, Grant $351.0K
- 2025: License And Service $74M, Grant $425.0K
| Product | 2023 | 2024 | 2025 | Share 2025 |
|---|---|---|---|---|
| License And Service | $44M | $58M | $74M | 99% |
| Grant | $699.0K | $351.0K | $425.0K | 0.6% |
By segment
RXRX's revenue by product line from 2019 to 2022, 4 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the XBRL of 5 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Dec 31, 2025Operating leases
$59M
Finance leases
$18M
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Goodwill by segment
Dec 31, 2025Total goodwill
$162M
The company does not state its goodwill by segment, at December 31, 2025. The filing
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
0.2%
The company paid 0.2% in tax on its profit, 20.8 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Change in valuation allowance · United States
-19.8 pts
Difference the filing does not itemize
-1.0 pts
Effective rate
0.2%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
The full analysis
What do Recursion Pharmaceuticals's filings show?
These are Recursion Pharmaceuticals's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did RXRX have in 2025?
Recursion Pharmaceuticals had revenue of $75M and net income of -$645M in fiscal 2025, a net margin of -863.4%.
How much debt does RXRX have?
On December 31, 2025 Recursion Pharmaceuticals had total assets of $1.5B, debt of $19M and shareholders' equity of $1.1B.
How much free cash flow does RXRX have?
In fiscal 2025 Recursion Pharmaceuticals had cash from operations of -$372M and spent $6.5M on capital expenditure, leaving -$378M of free cash flow.
Where are the figures from?
From Recursion Pharmaceuticals, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.